Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy

Bernhard Gentner, Ilaria Visigalli, Hidefumi Hiramatsu, Eric Lechman, Silvia Ungari, Alice Giustacchini, Giulia Schira, Mario Amendola, Angelo Quattrini, Sabata Martino, Aldo Orlacchio, John E. Dick, Alessandra Biffi, Luigi Naldini

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene. Hematopoietic stem cell (HSC)-based gene therapy is being explored for GLD; however, we found that forced GALC expression was toxic to HSCs and early progenitors, highlighting the need for improved regulation of vector expression. We used a genetic reporter strategy based on lentiviral vectors to detect microRNA activity in hematopoietic cells at single-cell resolution. We report that miR-126 and miR-130a were expressed in HSCs and early progenitors from both mice and humans, but not in differentiated progeny. Moreover, repopulating HSCs could be purified solely on the basis of miRNA expression, providing a new method relevant for human HSC isolation. By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells. This approach protected HSCs from GALC toxicity and allowed successful treatment of a mouse GLD model, providing a rationale to explore HSC-based gene therapy for GLD.

Original languageEnglish
Article number58ra84
JournalScience Translational Medicine
Volume2
Issue number58
DOIs
Publication statusPublished - Nov 17 2010

Fingerprint

Galactosylceramidase
Globoid Cell Leukodystrophy
Hematopoietic Stem Cells
MicroRNAs
Genetic Therapy
Cell Separation
Poisons
Mutation
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. / Gentner, Bernhard; Visigalli, Ilaria; Hiramatsu, Hidefumi; Lechman, Eric; Ungari, Silvia; Giustacchini, Alice; Schira, Giulia; Amendola, Mario; Quattrini, Angelo; Martino, Sabata; Orlacchio, Aldo; Dick, John E.; Biffi, Alessandra; Naldini, Luigi.

In: Science Translational Medicine, Vol. 2, No. 58, 58ra84, 17.11.2010.

Research output: Contribution to journalArticle

Gentner, B, Visigalli, I, Hiramatsu, H, Lechman, E, Ungari, S, Giustacchini, A, Schira, G, Amendola, M, Quattrini, A, Martino, S, Orlacchio, A, Dick, JE, Biffi, A & Naldini, L 2010, 'Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy', Science Translational Medicine, vol. 2, no. 58, 58ra84. https://doi.org/10.1126/scitranslmed.3001522
Gentner, Bernhard ; Visigalli, Ilaria ; Hiramatsu, Hidefumi ; Lechman, Eric ; Ungari, Silvia ; Giustacchini, Alice ; Schira, Giulia ; Amendola, Mario ; Quattrini, Angelo ; Martino, Sabata ; Orlacchio, Aldo ; Dick, John E. ; Biffi, Alessandra ; Naldini, Luigi. / Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. In: Science Translational Medicine. 2010 ; Vol. 2, No. 58.
@article{6bdf4bc87ef64bcc8fb1ec7406212a2c,
title = "Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy",
abstract = "Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene. Hematopoietic stem cell (HSC)-based gene therapy is being explored for GLD; however, we found that forced GALC expression was toxic to HSCs and early progenitors, highlighting the need for improved regulation of vector expression. We used a genetic reporter strategy based on lentiviral vectors to detect microRNA activity in hematopoietic cells at single-cell resolution. We report that miR-126 and miR-130a were expressed in HSCs and early progenitors from both mice and humans, but not in differentiated progeny. Moreover, repopulating HSCs could be purified solely on the basis of miRNA expression, providing a new method relevant for human HSC isolation. By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells. This approach protected HSCs from GALC toxicity and allowed successful treatment of a mouse GLD model, providing a rationale to explore HSC-based gene therapy for GLD.",
author = "Bernhard Gentner and Ilaria Visigalli and Hidefumi Hiramatsu and Eric Lechman and Silvia Ungari and Alice Giustacchini and Giulia Schira and Mario Amendola and Angelo Quattrini and Sabata Martino and Aldo Orlacchio and Dick, {John E.} and Alessandra Biffi and Luigi Naldini",
year = "2010",
month = "11",
day = "17",
doi = "10.1126/scitranslmed.3001522",
language = "English",
volume = "2",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "58",

}

TY - JOUR

T1 - Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy

AU - Gentner, Bernhard

AU - Visigalli, Ilaria

AU - Hiramatsu, Hidefumi

AU - Lechman, Eric

AU - Ungari, Silvia

AU - Giustacchini, Alice

AU - Schira, Giulia

AU - Amendola, Mario

AU - Quattrini, Angelo

AU - Martino, Sabata

AU - Orlacchio, Aldo

AU - Dick, John E.

AU - Biffi, Alessandra

AU - Naldini, Luigi

PY - 2010/11/17

Y1 - 2010/11/17

N2 - Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene. Hematopoietic stem cell (HSC)-based gene therapy is being explored for GLD; however, we found that forced GALC expression was toxic to HSCs and early progenitors, highlighting the need for improved regulation of vector expression. We used a genetic reporter strategy based on lentiviral vectors to detect microRNA activity in hematopoietic cells at single-cell resolution. We report that miR-126 and miR-130a were expressed in HSCs and early progenitors from both mice and humans, but not in differentiated progeny. Moreover, repopulating HSCs could be purified solely on the basis of miRNA expression, providing a new method relevant for human HSC isolation. By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells. This approach protected HSCs from GALC toxicity and allowed successful treatment of a mouse GLD model, providing a rationale to explore HSC-based gene therapy for GLD.

AB - Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene. Hematopoietic stem cell (HSC)-based gene therapy is being explored for GLD; however, we found that forced GALC expression was toxic to HSCs and early progenitors, highlighting the need for improved regulation of vector expression. We used a genetic reporter strategy based on lentiviral vectors to detect microRNA activity in hematopoietic cells at single-cell resolution. We report that miR-126 and miR-130a were expressed in HSCs and early progenitors from both mice and humans, but not in differentiated progeny. Moreover, repopulating HSCs could be purified solely on the basis of miRNA expression, providing a new method relevant for human HSC isolation. By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells. This approach protected HSCs from GALC toxicity and allowed successful treatment of a mouse GLD model, providing a rationale to explore HSC-based gene therapy for GLD.

UR - http://www.scopus.com/inward/record.url?scp=78449270317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449270317&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3001522

DO - 10.1126/scitranslmed.3001522

M3 - Article

C2 - 21084719

AN - SCOPUS:78449270317

VL - 2

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 58

M1 - 58ra84

ER -